1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study.
Saved in:
| Title: | 1704P Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study. |
|---|---|
| Authors: | Saliby, R.M.1 (AUTHOR), Xie, W.2 (AUTHOR), Wells, J.C.3 (AUTHOR), Saad, E.1 (AUTHOR), Eid, M.1 (AUTHOR), Semaan, K.1 (AUTHOR), Labaki, C.4 (AUTHOR), Ferrier, E.5 (AUTHOR), Zarba, M.5 (AUTHOR), Ebrahimi, H.6 (AUTHOR), Suarez Rodriguez, C.7 (AUTHOR), Ruiz, J.M.8 (AUTHOR), Powles, T.B.9 (AUTHOR), Wood, L.A.10 (AUTHOR), De Velasco Oria, G.A.11 (AUTHOR), Takemura, K.12 (AUTHOR), Braun, D.A.13 (AUTHOR), Heng, D.Y.C.14 (AUTHOR), Choueiri, T.K.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1021-S1022. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
